公开(公告)号：US09989535B2

公开(公告)日：2018-06-05

申请号：US15282430

申请日：2016-09-30

申请人： Warp Drive Bio, Inc.

发明人： Gregory L. Verdine ,  M. James Nichols ,  Sharon A. Townson ,  Uddhav Kumar Shigdel ,  Seung-Joo Lee ,  Dylan T. Stiles ,  Neville J. Anthony

IPC分类号： G01N33/68 ,  C07K1/08 ,  C07K5/083 ,  C07K7/64 ,  C07K1/13 ,  C07K5/02 ,  C12Q1/533 ,  G01N33/566 ,  C07K5/062

CPC分类号： G01N33/6845 ,  C07K1/086 ,  C07K1/13 ,  C07K5/0215 ,  C07K5/06034 ,  C07K5/0808 ,  C07K7/64 ,  C07K7/645 ,  C12Q1/533 ,  G01N33/566 ,  G01N2333/82 ,  G01N2333/90209 ,  G01N2410/08 ,  G01N2500/02

摘要： The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

公开(公告)号：US09885084B2

公开(公告)日：2018-02-06

申请号：US15649098

申请日：2017-07-13

申请人： Becton, Dickinson and Company

发明人： Song Shi ,  Richard L. Moore ,  James Garrett

IPC分类号： C12Q1/68 ,  G01N33/74 ,  G01N33/92

CPC分类号： C12Q1/6881 ,  C12Q2600/158 ,  G01N33/74 ,  G01N33/92 ,  G01N2333/90209 ,  G01N2333/91051 ,  G01N2800/26

摘要： The present invention relates to methods, monitors and systems, useful, for example, for advanced detection of sepsis in a subject.

公开(公告)号：US20170276665A1

公开(公告)日：2017-09-28

申请号：US15308836

申请日：2015-05-06

申请人： BLOODWORKS

发明人： James Charles Zimring ,  Karen S. de Wolski

IPC分类号： G01N33/50 ,  G01N33/80 ,  G01N33/53

CPC分类号： G01N33/5005 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/48 ,  G01N33/53 ,  G01N33/80 ,  G01N2333/82 ,  G01N2333/90209 ,  G01N2800/7066

摘要： Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.

公开(公告)号：US20170226228A1

公开(公告)日：2017-08-10

申请号：US15321015

申请日：2015-06-26

申请人： Yale University

发明人： Gary Desir ,  Abigail Hunt ,  Jessica O-Rear ,  Peter Flynn

IPC分类号： C07K16/40 ,  A61K39/395

CPC分类号： C07K16/40 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12Y106/03 ,  G01N33/573 ,  G01N2333/90209

摘要： The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.

公开(公告)号：US20170097359A1

公开(公告)日：2017-04-06

申请号：US15282430

申请日：2016-09-30

申请人： Warp Drive Bio, Inc.

发明人： Gregory L. VERDINE ,  M. James NICHOLS ,  Sharon A. TOWNSON ,  Uddhav Kumar SHIGDEL ,  Seung-Joo LEE ,  Dylan T. STILES ,  Neville J. ANTHONY

IPC分类号： G01N33/68 ,  C07K5/083 ,  C07K7/64 ,  C07K1/08

CPC分类号： G01N33/6845 ,  C07K1/086 ,  C07K1/13 ,  C07K5/0215 ,  C07K5/06034 ,  C07K5/0808 ,  C07K7/64 ,  C07K7/645 ,  C12Q1/533 ,  G01N33/566 ,  G01N2333/82 ,  G01N2333/90209 ,  G01N2410/08 ,  G01N2500/02

摘要： The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

公开(公告)号：US09612243B1

公开(公告)日：2017-04-04

申请号：US15169205

申请日：2016-05-31

申请人： Mor-NuCo Enterprises, Inc.

发明人： D. James Morre

IPC分类号： G01N33/574

CPC分类号： G01N33/57488 ,  C07K16/40 ,  C07K2317/56 ,  C07K2317/622 ,  C12Q1/26 ,  C12Y106/00 ,  G01N21/49 ,  G01N33/561 ,  G01N33/57492 ,  G01N2333/47 ,  G01N2333/90209

摘要： The present invention includes methods for detecting benign to malignant transformation of a cancer in a subject, comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretically separated ENOX2 transcript variants with an ENOX2 electron donor; and detecting the presence of the one or more activated ENOX2 transcript variants using a pan-ENOX2 detectable binding reagent, wherein the presence of one or more activated ENOX2 transcript variants in the sample is indicative of the malignant transformation of the cancer, whereby a 10 to 100 fold increase in detection sensitivity is obtained for the one or more activated ENOX2 transcript variants when compared to an equivalent non-activated ENOX2 transcript variant.

公开(公告)号：US20170030919A1

公开(公告)日：2017-02-02

申请号：US15205830

申请日：2016-07-08

申请人： Mor-NuCo Enterprises, Inc.

发明人： D. James Morre ,  Brandon Eugene Hostetler ,  James Jinpal Kim

IPC分类号： G01N33/574 ,  C12N9/02 ,  G01N27/447 ,  C07K14/79 ,  C12N9/16 ,  C12N9/96 ,  C07K16/40 ,  C07K14/81

CPC分类号： G01N33/57492 ,  C07K14/79 ,  C07K14/8125 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/622 ,  C07K2319/61 ,  C12N9/0036 ,  C12N9/16 ,  C12N9/96 ,  C12Y106/00 ,  C12Y301/03001 ,  G01N27/44726 ,  G01N27/4473 ,  G01N27/44747 ,  G01N27/44795 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57488 ,  G01N2333/705 ,  G01N2333/902 ,  G01N2333/90209 ,  G01N2333/916

摘要： Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.

摘要翻译： 不同细胞或组织起源的癌症表达不同的ENOX2癌症同种型或同种型的组合，并将这些蛋白质转移到循环中。 本文公开了用于癌症检测和特定来源诊断的方法，其基于允许鉴定肿瘤起始细胞类型和/或组织的同种型的模式和分子量。 相对的ENOX2量与肿瘤负荷成比例，并提供对治疗和疾病进展的可靠测量。 还提供了scFv抗体结合的氨基酸序列作为测试特异性的分子基础。

公开(公告)号：US20160376340A1

公开(公告)日：2016-12-29

申请号：US15192064

申请日：2016-06-24

申请人： Roberto Paterno ,  Mariarosaria Santillo ,  Vittorio Enrico Avvedimento ,  Luigi Michele Pavone

发明人： Roberto Paterno ,  Mariarosaria Santillo ,  Vittorio Enrico Avvedimento ,  Luigi Michele Pavone

IPC分类号： C07K14/705 ,  C07K16/28 ,  C07K16/40 ,  C12N9/02 ,  G01N33/564

CPC分类号： C07K14/70571 ,  A61K38/00 ,  A61K39/0008 ,  C07K16/286 ,  C07K16/40 ,  C12N9/0036 ,  C12Y106/03001 ,  G01N33/564 ,  G01N33/942 ,  G01N2333/70571 ,  G01N2333/90209 ,  G01N2800/285 ,  G01N2800/52

摘要： The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.

摘要翻译： 发现5-羟色胺受体5HT2A（5HT2aR）和膜NADPH氧化酶（NOX酶）是存在于多发性硬化症患者中的自身抗体的靶标。 本发明涉及包含在人5HT2aR和/或NOXs的细胞外区域中用于多发性硬化症诊断和治疗的肽。

公开(公告)号：US09439898B2

公开(公告)日：2016-09-13

申请号：US14296477

申请日：2014-06-05

申请人： Macau University of Science and Technology

发明人： Elaine Lai-Han Leung ,  Liang Liu ,  Xing-Xing Fan

IPC分类号： C12Q1/68 ,  A61K31/4741 ,  A61K33/40 ,  G01N33/50

CPC分类号： A61K31/4741 ,  A61K33/40 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/5011 ,  G01N2333/90209 ,  G01N2333/91205 ,  A61K2300/00

摘要： The present invention relates to methods for novel drug discovery, treatment and selective targeting for Gefitinib-resistant non-small-cell lung cancer (NSCLC) harboring an additional mutation, in particular, to the discovery of a drug candidate or agent identified by the presently claimed method for use in treating and selective targeting Gefitinib-resistant NSCLC harboring T790M mutation.

摘要翻译： 本发明涉及具有另外突变的吉非替尼耐药性非小细胞肺癌（NSCLC）的新药物发现，治疗和选择性靶向的方法，特别涉及目前鉴定的候选药物或药物的发现 所述方法用于治疗和选择性靶向具有T790M突变的吉非替尼耐药性NSCLC。

公开(公告)号：US20160235821A1

公开(公告)日：2016-08-18

申请号：US15087563

申请日：2016-03-31

申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

发明人： Mi Sun WON ,  Hyun Seung BAN ,  Bo Kyung KIM ,  Soon Woo NAM ,  Kyeong LEE ,  Young-Ju LEE ,  Hong-Sub LEE ,  Dong Uk KIM ,  Ki Cheol PARK ,  Joo-Young IM ,  Kyoung-Jin OH

IPC分类号： A61K38/44 ,  G01N33/574 ,  C12N7/00

CPC分类号： A61K38/44 ,  A61K48/005 ,  C12N7/00 ,  C12N9/004 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12Y106/02002 ,  G01N33/57492 ,  G01N2333/90209

摘要： The present invention relates to a pharmaceutical composition for treating cancer, containing cytochrome b5 reductase 3 (CYB5R3) protein as an active ingredient. Over-expression of CYB5R3 in cancer cells results in significant reduction of hypoxia-inducible factor-1α (HIF-1α) expression, which leads inhibition of cancer cells growth in vitro and in vivo. Thus, the CYB5R3 gene or protein of the present invention can be useful as an active ingredient of a pharmaceutical composition for treating cancer.

摘要翻译： 本发明涉及用于治疗癌症的药物组合物，其含有细胞色素b5还原酶3（CYB5R3）蛋白作为活性成分。 癌细胞中CYB5R3的过度表达导致缺氧诱导因子-1α（HIF-1α）表达的显着降低，这导致体外和体内癌细胞生长的抑制。 因此，本发明的CYB5R3基因或蛋白质可以用作治疗癌症的药物组合物的活性成分。